Crinetics Pharmaceuticals, Inc. (CRNX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '17: 2M Q1 '18: 2.4M Q2 '18: 2.3M Q3 '18: 2.2M Q4 '18: 2.4M Q1 '19: 2.4M Q2 '19: 1.7M Q3 '19: 1.7M Q4 '19: 1.2M Q1 '20: 897K Q2 '20: 897K Q3 '20: 392K Q4 '20: 71K Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 3.1M Q2 '22: 3.6M Q3 '22: 4M Q4 '23: 4M Q1 '24: 2M Q2 '24: 1.4M Q3 '24: 1M Q4 '24: 1M Q1 '25: 760K Q2 '25: 1.4M Q3 '25: 1.5M Q4 '25: 7.7M Q1 '26: 18.1M Q2 '26: 42.2M Q2 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q4 '17: -9.1M Q1 '18: -12M Q2 '18: -16.1M Q3 '18: -21.8M Q4 '18: -28.7M Q1 '19: -33.2M Q2 '19: -40.9M Q3 '19: -48M Q4 '19: -53.8M Q1 '20: -61.6M Q2 '20: -65.2M Q3 '20: -68.4M Q4 '20: -75M Q1 '21: -80.1M Q2 '21: -89.2M Q3 '21: -98.6M Q4 '21: -107.7M Q1 '22: -118.6M Q2 '22: -135.6M Q3 '22: -151.2M Q4 '22: -167.9M Q1 '23: -182M Q2 '23: -192M Q3 '23: -207.5M Q4 '23: -222.6M Q1 '24: -248.2M Q2 '24: -277.9M Q3 '24: -306.8M Q4 '24: -338.9M Q1 '25: -376.7M Q2 '25: -423.1M Q3 '25: -477.8M Q4 '25: -516.8M Q1 '26: -545.7M Q2 '26: -549.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q4 '17: -9.2M Q1 '18: -12M Q2 '18: -15.9M Q3 '18: -21.1M Q4 '18: -27.1M Q1 '19: -30.7M Q2 '19: -37.5M Q3 '19: -44.4M Q4 '19: -50.4M Q1 '20: -58.8M Q2 '20: -62.8M Q3 '20: -66.7M Q4 '20: -73.8M Q1 '21: -79.4M Q2 '21: -89M Q3 '21: -98.5M Q4 '21: -107.6M Q1 '22: -119.4M Q2 '22: -135.6M Q3 '22: -149.7M Q4 '22: -163.9M Q1 '23: -175.3M Q2 '23: -183.9M Q3 '23: -199.4M Q4 '23: -214.5M Q1 '24: -235.5M Q2 '24: -258.5M Q3 '24: -277.9M Q4 '24: -298.4M Q1 '25: -328.3M Q2 '25: -369.8M Q3 '25: -423.1M Q4 '25: -465.3M Q1 '26: -496.4M Q2 '26: -501.6M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '18: -12.7M Q3 '18: -16M Q4 '18: -19.5M Q1 '19: -22.8M Q2 '19: -31M Q3 '19: -38.9M Q4 '19: -46.4M Q1 '20: -51.9M Q2 '20: -55.1M Q3 '20: -59.5M Q4 '20: -62M Q1 '21: -69.9M Q2 '21: -74M Q3 '21: -81.6M Q4 '21: -88.6M Q1 '22: -82.1M Q2 '22: -90.1M Q3 '22: -102.9M Q4 '22: -115.2M Q1 '23: -142.4M Q2 '23: -160.1M Q3 '23: -163M Q4 '23: -168.6M Q1 '24: -180.7M Q2 '24: -182.6M Q3 '24: -204.1M Q4 '24: -230.2M Q1 '25: -265.8M Q2 '25: -304M Q3 '25: -351.9M Q4 '25: -377.9M Q1 '26: -414.2M Q2 '26: -422.5M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '18: -13.5M Q3 '18: -17M Q4 '18: -20.5M Q1 '19: -24.2M Q2 '19: -32M Q3 '19: -39.7M Q4 '19: -46.9M Q1 '20: -52M Q2 '20: -55.2M Q3 '20: -59.7M Q4 '20: -62.2M Q1 '21: -70.1M Q2 '21: -74.3M Q3 '21: -82.1M Q4 '21: -89M Q1 '22: -82.5M Q2 '22: -90.9M Q3 '22: -104.3M Q4 '22: -116.9M Q1 '23: -144M Q2 '23: -161.3M Q3 '23: -167M Q4 '23: -173.3M Q1 '24: -186.7M Q2 '24: -189.4M Q3 '24: -207.9M Q4 '24: -234M Q1 '25: -269.5M Q2 '25: -310M Q3 '25: -358.2M Q4 '25: -383.7M Q1 '26: -419.5M Q2 '26: -425.2M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '21: 37.1M Q3 '21: 38.3M Q1 '22: 47.7M Q2 '22: 52.5M Q3 '22: 53.8M Q1 '23: 53.9M Q2 '23: 54.3M Q3 '23: 56.8M Q1 '24: 72.3M Q2 '24: 79M Q3 '24: 80.1M Q1 '25: 93.1M Q2 '25: 93.8M Q3 '25: 94.2M Q1 '26: 104.1M Q2 '26: 105.6M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '17: -6.75 Q1 '18: -7.49 Q2 '18: -8.68 Q3 '18: -7.39 Q4 '18: -6.06 Q1 '19: -3.51 Q2 '19: -1.61 Q3 '19: -1.83 Q4 '19: -2.08 Q1 '20: -2.42 Q2 '20: -2.44 Q3 '20: -2.40 Q4 '20: -2.46 Q1 '21: -2.44 Q2 '21: -2.61 Q3 '21: -2.78 Q4 '21: -2.79 Q1 '22: -2.83 Q2 '22: -2.94 Q3 '22: -2.99 Q4 '22: -3.15 Q1 '23: -3.27 Q2 '23: -3.40 Q3 '23: -3.63 Q4 '23: -3.68 Q1 '24: -3.76 Q2 '24: -3.76 Q3 '24: -3.71 Q4 '24: -3.70 Q1 '25: -3.81 Q2 '25: -4.10 Q3 '25: -4.52 Q4 '25: -4.94 Q1 '26: -5.13 Q2 '26: -5.04 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.